692 results on '"Hori, Hikaru"'
Search Results
2. Lower plasma tumor necrosis factor-α is associated with symptomatic remission in patients with schizophrenia
3. Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo
4. Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project
5. Effect of the guideline education program on anticholinergic and benzodiazepine use in outpatients with schizophrenia and major depressive disorder: The effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE) project
6. Appropriate duration of antidepressant medications for prevention of depressive relapse and the impact of life stage
7. Cognitive improvement in patients with major depressive disorder after personalised multi domain training in the CERT-D study
8. Bipolar disorder and Lewy body dementia: case report and literature review
9. Characteristics of the treatments for each severity of major depressive disorder: A real-world multi-site study
10. The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project
11. The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project
12. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study
13. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial
14. Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib
15. Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project
16. Psychological training to improve psychosocial function in patients with major depressive disorder: A randomised clinical trial
17. Association between organizational justice and serious psychological distress among hospital nursing staff during the COVID‐19 pandemic: A cross‐sectional study.
18. Exploratory study of association between blood immune markers and cognitive symptom severity in major depressive disorder: Stratification by body mass index status
19. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis
20. Deciphering reward-based decision-making in schizophrenia: A meta-analysis and behavioral modeling of the Iowa Gambling Task
21. Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis.
22. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study
23. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study
24. Benzodiazepine withdrawal catatonia after discontinuing midazolam in young patient with intellectual developmental disorder: A case report
25. Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta‐analysis
26. Effects of Exercise on Functional Recovery in Patients with Bipolar Depression: A Study Protocol for a Randomized Controlled Trial
27. Evaluation of Changes in Anxiety, Depression, Social Behavior, and Oxytocin mRNA Levels in Adults after Adolescent Interventions in Maternal-separated Mice
28. Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics
29. Tardive dystonia improved with discontinuation of trazodone in an elderly schizophrenia patient: a case report
30. Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia
31. Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale–Japanese version
32. Change of prescription for patients with schizophrenia or major depressive disorder during admission: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education psychiatric treatment project
33. Management of unspecified anxiety disorder: Expert consensus
34. Management of unspecified anxiety disorder: Expert consensus
35. Decreased Activity at the Time of Return to Work Predicts Repeated Sick Leave in Depressed Japanese Patients
36. Clinical practice for unspecified anxiety disorder in primary care.
37. Successful treatment of switching from benzodiazepine to orexin receptor antagonists improves cognitive function in psychiatric disorders: four case reports
38. Satisfaction with web‐based courses on clinical practice guidelines for psychiatrists: Findings from the “Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)” project
39. Development of an individual fitness score ( IFS ) based on the depression treatment guidelines of in the Japanese Society of Mood Disorders
40. Effects of electroconvulsive therapy on the use of anxiolytics and sleep medications: a propensity score‐matched analysis
41. Corrigendum to ‘No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial’ [European Neuropsychopharmacology 53 (2021) 34–46]
42. Immunoglobulin genotypes and cognitive functions in schizophrenia
43. Motor Functional Characteristics in Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorders: A Systematic Review
44. Development of individual fitness score for conformity of prescriptions to the “Guidelines For Pharmacological Therapy of Schizophrenia”
45. Second-Generation Antipsychotic Monotherapy Contributes to the Discontinuation of Anticholinergic Drugs in Hospitalized Patients With Schizophrenia
46. Mood Stabilizers and Antipsychotics for Acute Mania: Systematic Review and Meta-Analysis of Augmentation Therapy vs Monotherapy From the Perspective of Time to the Onset of Treatment Effects
47. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients
48. Current smoking rate in patients with psychiatric disorders in Japan: Questionnaire survey
49. Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
50. Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.